OSE-279

N/A

Report date: 2024/10/24 16:48:44

First In Class

Base Information

Drug NameOSE-279

Drug Alias NameOSE-279

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsInterleukin-7 receptors stimulantsT lymphocytes stimulants +[4]

TargetsInterleukin-7 receptorsProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumFranceSpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesOse Immunotherapeutics

China Registration ClassN/A

Develop Information

Active CompaniesOse Immunotherapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A